The company reported 75.9 million shares of common stock outstanding as of March 31, based on the conversion of 15.6 million shares of convertible preferred stock into 1 .6 million shares of common stock in May and the automatic conversion of the remaining outstanding shares of convertible preferred stock into 63.3 million shares of common stock immediately prior to the IPO's closing

The compound is currently undergoing early stage clinical trials for the treatment of leukemia and solid tumor cancer, with rights to all oncology applications licensed to its partner, Eisai Co...In addition, the underwriters have a 30-day option to purchase up to an additional 486, 110 shares of common stock to cover overallotments, if any...The offering is expected to close on June 17.

In addition, Kamada has granted the underwriters a 30-day option to purchase up to an additional 837,395 shares of common stock to cover overallotments, if any...Proceeds will be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories for marketing AAT product Glassia and for general corporate purposes

The company issued approximately 11.5 million shares of common stock in connection with the warrant exercises

In its S-1, the company reported 18.4 million shares of common stock outstanding as of March 31...Since we're not going to have clinical data at the time we would expect the IPO – we're looking for funding to go into the clinic – the intent is that we try to produce as much preclinical data as we can," Harish said

Apricus Biosciences Inc., of San Diego, priced an underwritten public offering of 6 million shares of common stock at $2.85 per share and warrants to purchase up to an aggregate of 3 million shares of common stock, for proceeds of $17.1 million...The company said proceeds will be used for general corporate purposes, including clinical trial expenses and additional regulatory efforts related to erectile dysfunction drug Vitaros (alprostadil 0.3 percent topical cream) and female sexual dysfunction

Portola priced 8,422,758 shares of common stock at $14.50 per share, with a 30-day option for underwriters to purchase an additional 1,263,413 shares to cover overallotments

Funds will be used to support ongoing and new clinical trials and development and commercialization of Parkinson's psychosis drug pimavanserin and for general corporate purposes...and to fund linaclotide development opportunities to strengthen the clinical profile of Linzess and expand the product label for additional populations and indications...NPS Pharmaceuticals Inc., of Bedminster, N.J., is commencing a public offering of 6 million shares of common stock

The company said it had 1.1 million shares of common stock outstanding as of May 15 and 14.2 million additional shares that would be issued upon the automatic conversion of outstanding shares of its preferred stock at the offering's close

Proceeds will be used to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin, as well as activities for other product candidates and for general corporate purposes...Those personalized and targeted immunotherapies are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage and prior treatments. (See BioWorld Today, Oct. 17, 2012...Receptos will use the proceeds to support clinical work in multiple sclerosis

Omeros Corp., of Seattle, said it closed the registered direct offering of 3.9 million shares of common stock priced at $4.14 per share, raising net proceeds of about $16.1 million

Under the terms of its financing deal, Dyax priced a total of 8.9 million shares of common stock and 41,418 shares of Series 1 convertible preferred stock...MediciNova Inc., of San Diego, entered a securities purchase agreement, selling about 1.2 million shares of common stock priced at $3.15 apiece

Discovery Laboratories Inc., of Warrington, Pa., said it priced a $14.25 million public offering of 9.5 million shares of common stock at $1.50, an 8.5 percent discount to Thursday's closing price

In its filing, Isis said it would have 111.7 million shares of common stock outstanding when the offering closes...Isis has 28 candidates in preclinical and clinical development across a wide variety of indications, with nine scheduled to report data in the next 12 months

Receptos Inc., of San Diego, priced its initial public offering (IPO) of 5.2 million shares of common stock at $14 per share, for a total raise of $72.8 million...The funds will support clinical work in multiple sclerosis (MS), inflammatory bowel disease (IBD) and allergic/immune-mediated disorders. (See BioWorld Today, April 8, 2013.) The pricing hits pretty close to the $86.3 million target set when the company filed for its offering only a month ago...Chardan Capital Markets LLC acted as exclusive

The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Also in the pipeline: Lumena has licensed the patent rights and a package of clinical and non-clinical data for LUM002, another inhibitor of ASBT, also previously in development at the Phase I stage as a cholesterol-lowering agent by Paris-based Sanofi SA...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year

Warrants to purchase 0.28 shares of common stock were issued for each share of common stock purchased...An additional 1,923,599 shares of common stock and corresponding warrants were issued at the final closing to certain existing stockholders of the company who participated in earlier closings of this financing

The company plans to issue approximately 14.3 million shares of common stock and 9,900 shares of Series B convertible preferred stock at closing, expected on or about May 3

AG014 comprises oral delivery of an anti-TNF antibody with proven clinical efficacy in IBD, resulting in local efficacy and an improved safety profile over systemic drugs...MediciNova Inc., of San Diego, said in an SEC filing that it entered an equity distribution agreement with Macquarie Capital Inc. (MCUS) to sell shares of common stock up to an aggregate of $6 million from time to time, through MCUS as sales agent...Shares of Northwest (NASDAQ:NWBO) fell 13 cents to close Thursday at $3.77